Astrazeneca Reports Strong First-Half Performance Amid Mixed Pipeline Results
Astrazeneca reported first-half 2026 revenue growth of 6% at constant exchange rates, or 11% excluding the impact of generic competition. Core earnings per share increased by 11%, and the company reaffirmed its full-year outlook as well as its long-term goal to reach $80 billion in annual revenue by 2030. Oncology was a key growth driver, with revenue rising 15% year-over-year to $14.1 billion, fueled by products like CALQUENCE, Enhertu, and Imfinzi. The company also announced positive Phase III results for soniV in advanced gastric cancer and the combination of Imfinzi plus enfortumab vedotin in bladder cancer. However, AstraZeneca faced mixed pipeline outcomes: it initiated a comprehensive Phase III trial for obesity drug elecoglipron after promising early data but reported that its cardiovascular candidate Wainua failed to meet primary endpoints. Biopharmaceutical revenue declined 5% due to generic competition affecting products like Farxiga.
Tickers: $AZN
Topics: oncology drugs pharmaceuticals pipeline updates revenue growth